Clinical Trial: A one-arm，single center study on the efficacy and safety of Iparomlimab/Tuvonralimab (PD-1/CTLA-4 bispecific antibody) in combination with platinum-containing chemotherapy and bevacizumab in the treatment of persistent, recurrent cervical cancer after pelvic excision (China)

China, Aug. 31 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A one-arm，single center study on the efficacy and safety of Iparomlimab/Tuvonralimab (PD-1/CTLA-4 bispecific antibody) in combination with platinum-containing chemotherapy and bevacizumab in the treatment of persistent, recurrent cervical cancer after pelvic excision'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131148

Registration Time: 2026/08/28

Type: Interventional study

Primary Sponsor: The First Hospital of Jilin University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=330716

Published by HT Digital Content Services with permission from Heal...